HIV重症成人结核分枝杆菌血流感染:患病率、诊断与死亡风险的系统综述与个体患者数据Meta分析
该系统综述与个体患者数据Meta分析纳入20个数据集共5751例HIV感染且符合WHO疑似结核标准的患者,评估结核分枝杆菌血流感染的患病率、诊断效能及死亡风险。
要点
- HIV相关结核住院患者中结核分枝杆菌血流感染预测概率达45%。
- 痰Xpert联合尿LAM可将诊断率从77%提高至89%。
核心结论
- 在HIV相关结核重症成人中,结核分枝杆菌血流感染常见且预测30天内死亡。
- 痰Xpert联合尿LAM可提高血流感染的诊断率。
- 抗结核治疗延迟可能增加血流感染患者死亡风险。
研究设计与样本
- 5751例患者符合统一纳入标准:年龄≥13岁、HIV阳性、有CD4计数、血培养结果有效且符合WHO疑似结核定义。
主要发现
- 住院HIV相关结核患者伴WHO危险征象且CD4计数76 cells/μL时,血流感染预测概率45%(95%CI 38-52)。
- 血流感染患者痰诊断效率77%(95%CI 63-87),联合尿LAM提高至89%(95%CI 80-94)。
临床怎么用
- 对HIV相关结核重症住院患者应警惕血流感染, especially when CD4计数低且伴WHO危险征象。
- 诊断时联合痰Xpert与尿LAM可提高结核分枝杆菌血流感染的检出率。
- 应尽早启动抗结核治疗,避免延迟超过4天以降低死亡风险。
局限性
- 多数研究在患者选择领域存在中度偏倚风险。
- 研究间异质性显著,受血培养次数、采血时机、住院设置和CD4计数等技术及患者因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical and epidemiological significance of HIV-associated Mycobacterium tuberculosis bloodstream infection (BSI) is incompletely understood. We hypothesised that M tuberculosis BSI prevalence has been underestimated, that it independently predicts death, and that sputum Xpert MTB/RIF has suboptimal diagnostic yield for M tuberculosis BSI. METHODS: We did a systematic review and individual patient data (IPD) meta-analysis of studies performing routine mycobacterial blood culture in a prospectively defined patient population of people with HIV aged 13 years or older. Studies were identified through searching PubMed and Scopus up to Nov 10, 2018, without language or date restrictions and through manual review of reference lists. Risk of bias in the included studies was assessed with an adapted QUADAS-2 framework. IPD were requested for all identified studies and subject to harmonised inclusion criteria: age 13 years or older, HIV positivity, available CD4 cell count, a valid mycobacterial blood culture result (excluding patients with missing data from lost or contaminated blood cultures), and meeting WHO definitions for suspected tuberculosis (presence of screening symptom). Predicted probabilities of M tuberculosis BSI from mixed-effects modelling were used to estimate prevalence. Estimates of diagnostic yield of sputum testing with Xpert (or culture if Xpert was unavailable) and of urine lipoarabinomannan (LAM) testing for M tuberculosis BSI were obtained by two-level random-effect meta-analysis. Estimates of mortality associated with M tuberculosis BSI were obtained by mixed-effect Cox proportional-hazard modelling and of effect of treatment delay on mortality by propensity-score analysis. This study is registered with PROSPERO, number 42016050022. FINDINGS: We identified 23 datasets for inclusion (20 published and three unpublished at time of search) and obtained IPD from 20, representing 96·2% of eligible IPD. Risk of bias for the included studies was assessed to be generally low except for on the patient selection domain, which was moderate in most studies. 5751 patients met harmonised IPD-level inclusion criteria. Technical factors such as number of blood cultures done, timing of blood cultures relative to blood sampling, and patient factors such as inpatient setting and CD4 cell count, explained significant heterogeneity between primary studies. The predicted probability of M tuberculosis BSI in hospital inpatients with HIV-associated tuberculosis, WHO danger signs, and a CD4 count of 76 cells per μL (the median for the cohort) was 45% (95% CI 38-52). The diagnostic yield of sputum in patients with M tuberculosis BSI was 77% (95% CI 63-87), increasing to 89% (80-94) when combined with urine LAM testing. Presence of M tuberculosis BSI compared with its absence in patients with HIV-associated tuberculosis increased risk of death before 30 days (adjusted hazard ratio 2·48, 95% CI 2·05-3·08) but not after 30 days (1·25, 0·84-2·49). In a propensity-score matched cohort of participants with HIV-associated tuberculosis (n=630), mortality increased in patients with M tuberculosis BSI who had a delay in anti-tuberculosis treatment of longer than 4 days compared with those who had no delay (odds ratio 3·15, 95% CI 1·16-8·84). INTERPRETATION: In critically ill adults with HIV-tuberculosis, M tuberculosis BSI is a frequent manifestation of tuberculosis and predicts mortality within 30 days. Improved diagnostic yield in patients with M tuberculosis BSI could be achieved through combined use of sputum Xpert and urine LAM. Anti-tuberculosis treatment delay might increase the risk of mortality in these patients. FUNDING: This study was supported by Wellcome fellowships 109105Z/15/A and 105165/Z/14/A.
引用
- Barr DA, Lewis JM, Feasey N, et al. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. Lancet Infect Dis. 2020. PMID: 32178764. doi:10.1016/S1473-3099(19)30695-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。